The report "BRIC IVD Market by Product &
Service (Instruments, Reagents, Software), Technology (Immunoassay, Hematology,
Microbiology), Application (Diabetes, Cardiology, Infectious Diseases), Country
(Brazil, Russia, India, China) - Forecast to 2022", The
BRIC IVD Market and other emerging countries is expected to reach USD 15.71
Billion by 2022 from USD 10.60 Billion in 2017, at a CAGR of 8.2%.
Browse 138
market data tables and 69 figures spread through 278 pages and in-depth TOC on "BRIC IVD Market “
http://www.marketsandmarkets.com/Market-Reports/ivd-bric-market-198.html
Early buyers will receive 10% customization on this reports
Early buyers will receive 10% customization on this reports
The rising incidence
of chronic diseases, growth in the number of private diagnostic centers, and
rising consolidation of laboratories are the key factors driving the market
growth. However, inadequate reimbursement and the slow growth of the economy
are the factors restraining the growth of this market.
This research study involved the extensive use of both primary and
secondary data sources as well as various factors affecting the industry,
including the regulatory landscape; competitive scenario; historic data;
current trends in the market; technological innovations and upcoming
technologies; and market drivers, restraints, opportunities, and challenges.
In this report, the BRIC In Vitro Diagnostics (IVD) Market is
segmented by product & service, technology, application, end user, and
country. Based on application, the market is segmented into diabetes,
infectious diseases, oncology/cancer, cardiology, HIV/AIDS, autoimmune
diseases, nephrology, drug testing/pharmacogenomics, and others. The infectious
diseases segment accounted for the largest share of the market in 2016, owing
to the rising incidence of tuberculosis (TB), hepatitis, and hospital-acquired
infections.
Based on technology, the BRIC IVD Market is broadly segmented into
immunoassays/immunochemistry, clinical chemistry, molecular diagnostics,
hematology, clinical microbiology, coagulation & hemostasis, and other
technologies. The molecular diagnostics segment is estimated to register the
highest CAGR during the forecast period of 2017 to 2022. The rising prevalence
of infectious diseases, cancer, and various genetic disorders; growing demand
for blood screening; and increasing application of molecular diagnostic
technologies in pharmacogenetics and point-of-care testing is expected to drive
the growth of the market during the forecast period.
The Sample Report For This
Report@
Geographically, China dominated the BRIC IVD Market and other
emerging countries in 2016. The large share of this country can be attributed
to rising healthcare expenditure, increasing acceptance of personalized
medicine, and increasing awareness towards technologically advanced products in
this country. China is also expected to register the highest CAGR, due to the
growth in research activities and increasing investments by leading players and
government agencies in the country.
The key players in this BRIC IVD Market are Roche Diagnostics
(Switzerland), Abbott Laboratories Inc. (U.S.), Siemens Healthineers (Germany),
Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Sysmex
Corporation (Japan), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux (France),
and Becton, Dickinson and Company (U.S.), Johnson & Johnson (U.S.), QIAGEN
N.V. (Germany), Ortho-Clinical Diagnostics, Inc. (U.S.), and Diasorin S.P.A.
(Italy).
Get The PDF Brochure For This Report@
About MarketsandMarkets™:
MarketsandMarkets™
provides quantified B2B research on 30,000 high growth niche
opportunities/threats which will impact 70% to 80% of worldwide companies’
revenues. Currently servicing 5000 customers worldwide including 80% of global
Fortune 1000 companies as clients. Almost 75,000 top officers across eight
industries worldwide approach MarketsandMarkets™ for their painpoints around
revenues decisions.
Our
850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high
growth markets following the "Growth Engagement Model – GEM". The GEM
aims at proactive collaboration with the clients to identify new opportunities,
identify most important customers, write "Attack, avoid and defend"
strategies, identify sources of incremental revenues for both the company and
its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants
(Positioning top players across leaders, emerging companies, innovators, strategic
players) annually in high growth emerging segments. MarketsandMarkets™ is
determined to benefit more than 10,000 companies this year for their revenue
planning and help them take their innovations/disruptions early to the market
by providing them research ahead of the curve.
MarketsandMarkets’s
flagship competitive intelligence and market research platform, "RT"
connects over 200,000 markets and entire value chains for deeper understanding
of the unmet insights along with market sizing and forecasts of niche
markets.
Contact:
Mr. Rohan
MarketsandMarkets™
701
Pike Street
Suite
2175, Seattle,
WA
98101, United States
Tel:
1-888-600-6441
No comments:
Post a Comment